Abstract 2047P
Background
Despite significant advances in prevention and treatment, febrile neutropenia (FN) remains a common and serious complication of chemotherapy. Leverages data related to G-CSF use are missing. This study aims to (1) describe the practices of G-CSF treatment implementation; (2) identify and measure the decision criteria related to their implementation in patients with breast (BC), lung (LC), or gastrointestinal cancers (GIC), in ambulatory settings, beyond the usual recommendations.
Methods
This non-interventional, cross-sectional, multicenter study required clinical cases presented using conversational interfaces (chatbot), simulating a conversation with one or several virtual interlocutors by voice or text exchange.
Results
The questionnaire was completed by 102 physicians. Most practitioners (84.5%) reported prescribing G-CSF, regardless of tumor type (Table). G-CSF was prescribed more frequently for adjuvant/neoadjuvant therapy than for metastatic cases. Leading factors motivating the prescription were chemotherapy regimen, comorbidities, and age (in 56.7% of cases). Access to care was cited as a reason to prescribe G-CSF.
Table: 2047P
Levels and reasons of G-CSF prescription in all 3 cancer types
Breast cancer | Lung cancer | Gastro Intestinal cancer | Total | ||
Implementation of a G-CSF treatment N (%) | N | 77 | 57 | 60 | 194 |
Yes | 68 (88.3%) | 42 (73.7%) | 54 (90.0%) | 164 (84.5%) | |
Not | 9 (11.7%) | 15 (26.3%) | 6 (10.0%) | 30 (15.5%) | |
What should be considered before prescribing a G-CSF for this patient? N (%) | N | 68 | 42 | 54 | 164 |
Chemotherapy Protocol | 23 (33.8%) | 9 (21.4%) | 7 (13.0%) | 39 (23.8%) | |
Chemotherapy Protocol + comorbidities | 12 (17.6%) | 2 (4.8%) | 8 (14.8%) | 22 (13.4%) | |
Chemotherapy Protocol + Age | 2 (2.9%) | 6 (14.3%) | 2 (3.7%) | 10 (6.1%) | |
Chemotherapy Protocol + comorbidities + age | 31 (45.6%) | 25 (59.5%) | 37 (68.5%) | 93 (56.7%) |
Conclusions
Our findings suggest that ESMO recommendations are broadly followed. In most cases, G-CSF is prescribed in early stages and in curative intent. Despite a large use of G-CSF, education about febrile neutropenia and risk factors should be disseminated to a wide audience.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Viatris.
Funding
Viatris.
Disclosure
F. Scotté: Financial Interests, Personal, Speaker, Consultant, Advisor: Leo Pharma, Pierre Fabre Oncology, MSD, Amgen, Helsinn, BMS, Pfizer, Thermo Fisher, Alliance Healthcare, Biogaran, Sandoz, Sanofi, Pharmanovia, Viatris.
Resources from the same session
2086P - Management of opioids use disorder in cancer survivors
Presenter: Khalida Berkane
Session: Poster session 06
2087P - Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
Presenter: Raffaele Giusti
Session: Poster session 06
2088P - Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Presenter: Anna Amela Valsecchi
Session: Poster session 06
2090P - Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice
Presenter: Luca Licata
Session: Poster session 06
2091P - Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses
Presenter: Pascale Dielenseger
Session: Poster session 06
2092P - Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors
Presenter: MACHEROUM Fatma zohra
Session: Poster session 06
2093P - Bioelectrical Impedance phase angle and obesity as a prognostic indicator in metastatic gastric cancer patients receiving second-line chemotherapy
Presenter: SangUk Han
Session: Poster session 06
2094P - A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Presenter: Shinya Takada
Session: Poster session 06
2095P - Cancer rehabilitation program for cancer-related fatigue
Presenter: Aizhan Bekisheva
Session: Poster session 06